Maiden Pharmaceuticals Refutes Allegations of Test Tampering Amid Investigation into Cough Syrup Deaths

In a recent statement, Maiden Pharmaceuticals, an Indian pharmaceutical company embroiled in a scandal regarding cough syrups allegedly linked to the deaths of children in Gambia, vehemently denied any wrongdoing. The firm stood firm against allegations of tampering with test samples and bribing officials to influence investigations.

The controversy erupted when the World Health Organisation (WHO) reported that toxic substances were found in cough syrups produced by Maiden Pharmaceuticals. The syrups were associated with the tragic deaths of 70 children in Gambia, causing global concern and prompting rigorous investigations. Contrary to the WHO's findings, subsequent testing by an Indian government laboratory declared the syrups free of toxins, which raised suspicions and led to further inquiry.

A high-level investigator within Haryana state's Food and Drug Administration, Gagandeep Singh, intimated that his probe into a potential bribe received by state drug regulator Manmohan Taneja was nearing its completion. Allegedly, a bribe amounting to 50 million Indian rupees was accepted to replace the test samples sent to the Indian lab, which diluted the results.

Naresh Kumar Goyal, the founder of Maiden Pharmaceuticals, categorically denied these allegations, stating, "I have never changed the sample. There is no evidence and no proof against us. I have not given a bribe." Goyal also dispelled any notions of being summoned by the investigator and suggested a competitor might be orchestrating the complaint against the company.

Amid the heated debate existing between Maiden's assertions and the WHO's statements, Maiden's manufacturing facility, which has been shut down since October 2022, is currently under renovation. Goyal expressed confidence in reopening the plant, adamantly affirming that any issues pointed out by the authorities have been rectified.

However, sources in the know have cast doubts on the prospects of a swift reopening of Maiden's factory and other Indian pharmaceutical factories linked to similar incidents in Uzbekistan and Cameroon. With a total of at least 141 reported deaths since the previous year, Indian government officials are treading cautiously given the sensitivity of the issue and its potential political ramifications, especially ahead of the general election in May.

As the health ministry remains silent, public trust in the pharmaceutical industry hangs in the balance while the investigation into Maiden Pharmaceuticals continues to unfold.